1 / 42

Massive Hemoptysis

Massive Hemoptysis. D. P. Laporta MD Departments of Adult Critical Care and Medicine, Sir MB Davis Jewish General Hospital McGill University presented to McGill Residents Critical Care (January 2000) Pulmonary (July July 2000. MASSIVE HEMOPTYSIS REFERENCES.

pippa
Download Presentation

Massive Hemoptysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Massive Hemoptysis D. P. Laporta MDDepartments of Adult Critical Care and Medicine, Sir MB Davis Jewish General HospitalMcGill Universitypresented to McGill ResidentsCritical Care (January 2000)Pulmonary (July July 2000

  2. MASSIVEHEMOPTYSISREFERENCES • Bone: Pulmonary & Critical Care Medicine, 1998 ed., 1998 Mosby-Year Book, Inc.Ch R19 Massive Hemoptysis • Ch M10 Pulmonary Hemorrhage Syndromes • Jean Baptiste E «clinical Assessment and management of massive hemoptysis Crit Care Med 2000; 28:1642-7 • Dweik RA, Stoller JK. Role of bronchoscopy in massive hemoptysis, in : Flexible bronchoscopy in the 21st century. Clin. Chest Med. 1999; 20(1) March • White R. Jr. Bronchial Artery Embolotherapy for Control of Acute Hemoptysis. Analysis of Outcome . Chest 1999; 115(4) April • Fanburg BL et al, Case 52-1993: A 17-Year-Old Girl with Massive Hemoptysis and Acute Oliguric Renal Failure. NEJM Weekly CPC. 1993; 329(27)

  3. MASSIVEHEMOPTYSIS NATURAL HISTORY AND PROGNOSIS • MORTALITY Immediate : 7% of 113 patients who presented with massivehemoptysis died soon after onset. Etiology : TB 18.6%, CF 32%, Other 10% • DURATION If survive the initial episode, bleeding stops <3-6 days • RECURRENCE RATE 20-46% after bronchial embolization

  4. MASSIVEHEMOPTYSIS Prognostic Features Associated with Death Magnitude of Bleed • bleeding exceeding 1000 mL/24 h 600 mL of hemoptysis in <4 hours 71%mortality 4-16 hous 22% 16-48 hours 5% • hemodynamic instability • CXR evidence of aspiration • bilateral bleeding sources • inability to localize source of bleeding • caused by a neoplasm • inadequate pulmonary function • debilitated states, and metastatic cancer • MORTALITY 80 % if > 1L/24 h PLUS malignancy + Underlying Etiology

  5. Overestimate Underestimate 400 ml = abN gas XC

  6. Hemoptysis: is it real ? • GI • Factitious (Munchausen ’s) • Pseudo: drugs (RFP, clofazimine) • Serratia pneumonia • ENT

  7. 90 %

  8. Bronchial Circulation • Come directly or indirectly from the aorta (T3-8) • Variability

  9. Nonbronchialsystemiccollateral arteries • in 45% of patients with hemoptysis • commonly: intercostal, subclavian, axillary & phrenics • uncommonly: IMA, thyrocervical, carotid, coronaries • Because of the many systemic arteries involved, routine arteriographic localization cannot be all-inclusive

  10. MASSIVEHEMOPTYSIS ETIOLOGY (1) Infectious(bacterial, mycobacterial, viral, fungal, parasitic)Lung abscess Bronchiectasis (including cystic fibrosis) Mycetoma (e.g., aspergilloma) Infected BP Sequestration Septic emboli Infected aortic graft Neoplasm Malignant Bronchogenic Metastasis from pulmonary/extrapulmonary Benign (bronchial adenoma)

  11. MASSIVEHEMOPTYSIS ETIOLOGY (2) Foreign body/traumaAspirated foreign bodyBroncholithTracheovascular fistulaTrauma, Brachytherapy, Laser Cardiac/pulmonary vascularPulmonary venous HTN Mitral stenosis, PVOD (Pulmonary embolus)Pulmonary artery Perforation (complicating Swan-Ganz catheter) Aneurysm/false (mycotic, Behcet’s, Hughes-Stovin) Arteriovenous malformations OWR, DieuLaFoye Fistulae (every vessel parring through the thorax)

  12. MASSIVEHEMOPTYSIS ETIOLOGY (3) Alveolar hemorrhage Goodpasture's syndrome Systemic vasculitides/collagen vascular diseases…capillaritisBehcet's syndromeEssential mixed cryoglobulinemia, Henoch-Schonlein purpuraProgressive systemic sclerosisRheumatoid arthritis, Systemic lupus erythematosus, Mixed connective tissue disease Systemic necrotizing vasculitis, Wegener's granulomatosis Other Glomerulonephritis Immune complex associated glomerulonephritisPauci-immune glomerulonephritis Familial Acute Leukemias

  13. MASSIVEHEMOPTYSIS ETIOLOGY (4) Drug-induced Cocaine, D-penicillamine, Isocyanates, Nitrofurantoin, Trimellitic anhydride Anticoags, Thrombolytics, ASA

  14. MASSIVEHEMOPTYSIS ETIOLOGY (4) Miscellaneous • Idiopathic hemosiderosis • Coagulation disorders Thrombotic thrombocytopenic purpura DIC Acquired coagulopathy (permissive) • Endometriosis (Catamenial hemoptysis) • Sarcoidosis • Lymphangioleiomyomatosis • Chronic Lung Disease • Emphysematous bullae • Pneumoconiosis

  15. MASSIVEHEMOPTYSISBEDSIDE ASSESSMENT OF THE PATIENT • Clubbing, Simian crease, Cutaneous nodules/pustules + uveitis • IVDU with septic thrombophlebitis, palpable purpura, malar rash • Oral: ulcers, mucosal telangiectasias, • Post-URI rhinitis, saddle nose • Stridor/wheezing

  16. MASSIVEHEMOPTYSISClinical History Young adult female ... • otherwise healthy • with recurrent CHF & A fib • with spontaneous pneumothorax + ILD • menstruating

  17. MASSIVEHEMOPTYSISClinical History Inflammatory Lung Diseases • bronchiectasis • abscess • necrotizing pneumonia • infected cavity/bulla (mycetoma)

  18. MASSIVEHEMOPTYSISClinical HistoryTUBERCULOSIS • more common in the presence of cavitary disease. • pathologic lesions • Rasmussen's aneurysms • bronchial artery erosions from tb airway inflammation or bronchiectasis; • secondary infections of prior tuberculous cavities (eg Aspergillus)

  19. Specific clinical situations presenting with MASSIVE HEMOPTYSIS • Tracheostomy • Post-Partum • Southeast Asia, Middle East • South America • Lymphoma • Acute Leukemia • Cardiac Surgery

  20. High-power magnification showing capillaritis, which is characterized by infiltration of the alveolar septae by neutrophils (arrow). Note the presence of scattered red cells in the parenchyma (H&E stain, original magnification × 400).

  21. DIFFUSE ALVEOLAR HEMORRHAGE • Bloody BAL fluid • hemosiderin-laden macrophages • lack of infectious pathogens • ...are sufficient to establish DAH.

  22. Causes of MH Associated With a Normal Chest Radiograph

  23. MANAGEMENT of MH 1. Make the right etiological DIAGNOSIS ! • Hx. Px, Sputum, Bloods, FOB, Imaging 2. Determine the SITE of bleeding • Hx, Px, CXR (?CT) • FOB : flexible, rigid • observe mucosa etc., washings: culture incl TB, cytology 3. Airway control/pt stabilization surgical candidate ? 4. Specific Therapy

  24. DOUBLE-LUMEN ETT IN MASSIVE HEMOPTYSIS • Requires expert • Small lumina : difficult insertion, easy obstruction • 62 patients with MH • 4/7 pts with DL-ETT : aspiration and death • cause : loss of tube position and pulmonary aspiration during surgery. • L bronchial ETI : 0/12 deaths from • L Fogarty- Tracheal ETI : aspiration

  25. TIMINGOF BRONCHOSCOPY The sicker, the earlier ! • site of bleeding visualized more commonly with early bronchoscopy (within 48 hours) • unlikely relevant in non-massive hemoptysis

  26. Management of MHBRONCHIAL ARTERY EMBOLIZATION (1) • successful immediate control 64% to100%. • Technical inability to cannulate : 13% • Recurrence of bleeding • Immediate 20-40% • Follow-up post BAE 1 year: 16 % 3 years : 23% • Complications : • vessel perforation/intimal tears • sequelae of bronchial artery occlusion (e.g., chest pain, fever, hemoptysis) • inadvertent ectopic emboli. • mesenteric occlusion • vessels supplying the extremities • ASA embolization • reduced withcoaxial microcatheter system :"superselective" ba catheterization/bae without occluding other branches

  27. Management of MHBRONCHIAL ARTERY EMBOLIZATION (2) • most difficult : identify the vessel(s) responsible for bleeding. • injection in the descending aorta just below the left subclavian artery • may require a full-arch aortogram in some • LL bleeding w/no apparent bronchial supply: • UL bleeding: unilateral subclavian artery injection to exclude nonbronchial systemic collateral arteries. • formal bronchial arteriogram • blush,abnormal vessels, ensures that no communication to the anterior spinal artery

  28. Intervention in MH: Medical or Surgical ? • Observational studies • no RCTs… selection bias • none used bae as part of medical therapy • wide range of mortality rates : • surgical (1-50%) and medical (1.6-85%) • results are mixed …lower surgical mortality rates

  29. Intervention in MH: Medical or Surgical ? • Current recommendations: surgical resection preferred if: • BAE unavailable or failed • imminent survival threatened by transport to radiology (ABCs) • surgically operable patient with a localized (ie resectable) lesion as cause of MH which is deemed unlikely to be controlled by BAE: • Thoracic vascular injury/trauma • mycetoma +profuse collateral arterial supply, • hydatid cyst • bronchial adenoma • AVM

  30. PA RUPTURE (1) • Epidemiology • Prevalence .06-.2% • Rebleed: 90 % within 3 days Mechanism: Pseudoaneurysm (Psan) • Mortality: all comers 45-65% if rebleed: 40-70% 26% if abnormal CXR is only manifest'n of PA rupture 65% if clinical hemorrhage (ie hemoptysis, hemothorax, parenchymal bleed - HHPB) • CXR may be normal despite PA rupture ? Psan

  31. PA RUPTURE (2) Contributory causes • technical errors (improper equipment, technique or judgment) • age > 60 • PA hypertension • anticoagulated • hypothermia • inhalational anesthetic agents • peri-CPB (especially intraop)

More Related